The Center for Biosimilars recaps the top 5 articles for the week of December 4.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 4.
Number 5: The efficient use of modeling and simulation may allow for better decision making that can increase the likelihood of successful outcomes in biosimilar development.
Number 4: At the American Society of Hematology’s 59th Annual Meeting and Exposition in Atlanta, Georgia, a research team will present findings that community-based lymphoma care is associated with guideline-discordant use of rituximab.
Number 3: Rival insulin makers Novo Nordisk and Sanofi both announced positive data on their products that could help them to stave off biosimilar and follow-on competition.
Number 2: Research shows that savings generated from the use of biosimilar filgrastim can expand access to high-cost drugs.
Number 1: A new report from the National Academy of Sciences, Engineering, and Medicine calls for big changes in how US pharmaceuticals are priced, promoted, and sold, so that treatments are more affordable and equally available to all Americans.
Finally, last week, our e-newsletter asked whether you think prescribers, patients, or payers are the key drivers of biosimilar uptake. To see results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.